AMGEN INC is 130.6x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($182.28 B vs $1.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GLUE | AMGN |
|---|---|---|
| Market cap | $1.40 B | $182.28 B |
| US-listed rank | #2377 | #80 |
| Revenue (latest FY) | $123.67M | $36.75B |
| Net income (latest FY) | -$38.60M | $7.71B |
| Net margin | -31.2% | 21.0% |
| P/E (trailing FY) | - | 23.6 |
| SEC filings | 352 | 1,011 |
AMGEN INC is 130.6x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($182.28 B vs $1.40 B).
In their latest fiscal years, Monte Rosa Therapeutics, Inc. reported $123.67M in revenue while AMGEN INC reported $36.75B.
Full pages: Monte Rosa Therapeutics, Inc. and AMGEN INC, or browse the full rankings.